Wockhardt Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Wockhardt Ltd. from all sources in a single place.

Load latest

Wockhardt Ltd.

07 Jan 2025

1296.70

-4.91%

Wockhardt Eyes Rs 400-Crore Revenue From Pneumonia Antibiotic Miqnaf

NDTV Profit

Miqnaf is an antibiotic for treatment of community-acquired bacterial pneumonia, including those caused by multi-drug resistant pathogens.

Promoters pledged 1.26% of shares in last quarter. Total pledge stands at 18.24% of promoter holdings

Wockhardt Ltd.

03 Jan 2025

1296.70

-4.91%

Wockhardt's novel antibiotic gets CDSCO approval

Business Line

The antibiotic is an ultra-short course - once-a-day, 3-day treatment for Community-Acquired Bacterial Pneumonia (CABP) in adults, including those caused by multi-drug resistant (MDR) pathogens, the company said

Wockhardt Ltd.'s price crossed below 50Day SMA today

Wockhardt shares surge 9.5%, touch 9-year high on regulatory nod for antibiotic drug

livemint | 03 Jan 2025 1 more

Wockhardt Ltd.

02 Jan 2025

1296.70

-4.91%

Company Update

WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of the Listing Regulations, please find attached Press Release titled- Indian Drug Regulator Approves Wockhardt''s New Generation Oral Antibiotic MiqnafR (Nafithromycin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP).

pdf

Wockhardt Ltd.

26 Dec 2024

1296.70

-4.91%

SAST

WOCKHARDT LTD. - 532300 - Closure of Trading Window

BSE India

This is to inform you that pursuant to Company''s Code of Conduct for regulating, monitoring and reporting trading by Designated persons, the trading window for dealing in the equity shares of the Company will be closed from 1st January, 2025 until 48 hours after the declaration of unaudited financial results for quarter and nine months ended on 31st December, 2024.

pdf

Wockhardt Ltd.

24 Dec 2024

1296.70

-4.91%

Murmu, VP Dhankhar, and LS Speaker Birla condole Shyam Benegal's demise

Business Standard

Benegal, a pivotal figure in Indian cinema, passed away on Monday at the age of 90 at Wockhardt Hospital, Mumbai Central

Wockhardt Ltd.'s price crossed below 50Day SMA today

Shyam Benegal no more: Look back at illustrious work of veteran filmmaker

Business Standard | 23 Dec 2024 1 more

Wockhardt Ltd.

16 Dec 2024

1296.70

-4.91%

Wockhardt's Zaynich gives new hope to cancer patient with successful liver transplant

Business Line

The drug effectively cleared a chronic bile duct infection, enabling the patient to undergo a liver transplant and resume chemotherapy.

Wockhardt Ltd.'s price crossed below 50Day SMA today

Wockhardt Share Price At Life High As Patent Drug Aids US Patient With Transplant Surgery

NDTV Profit | 16 Dec 2024 1 more

Wockhardt Ltd.

16 Dec 2024

1296.70

-4.91%

Company Update

WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of SEBI Listing Regulations, please find attached Press Release titled, "Zaynich TM (Zidebactam/Cefepime, WCK 5222) enables US cancer patient undergo successful liver transplant and resume chemotheraphy by eradicating dual extreme-drug resistant Gram negative pathogens"

pdf

Wockhardt Ltd.

06 Dec 2024

1296.70

-4.91%

Indigenous development of Nafithromycin marks key milestone in AMR battle: Government

Business Line

Developed by Wockhardt, it is a first in its class to be introduced globally in over 30 years

Wockhardt Ltd. has gained 128.92% in the last 1 Year

Wockhardt Ltd.

05 Dec 2024

1296.70

-4.91%

Indian pharma develops more effective drug to combat antibiotic-resistance

Business Standard

Wockhardt's nafithromycin is India's first FDA-approved antimicrobial that is seen as an alternative to existing antibiotics like azithromycin, which is facing increasing resistance in humans

Promoters pledged 1.26% of shares in last quarter. Total pledge stands at 18.24% of promoter holdings

Wockhardt Ltd.

27 Nov 2024

1296.70

-4.91%

Corp. Note

WOCKHARDT LTD. - 532300 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate …

BSE India

Pursuant to the requirement of the Regulation 39(3) of the SEBI Listing Regulations, we wish to inform you that our RTA has intimated about receipt of the request for the issuance of Duplicate Share Certificate in lieu of the Original Certificate lost/misplaced.

pdf

Is Wockhardt Ltd. worth buying?

443 Votes:

Buy 73.14%

Sell 17.38%

Hold 9.48%

164.55% Gain from 52W Low

Wockhardt Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Wockhardt Ltd. from all sources in a single place.